HALOBETASOL PROPIONATE COMPOSITIONS
In one example presented herein, is a pharmaceutical composition. The pharmaceutical composition can include halobetasol propionate, from 0 wt% to 3 wt% ethoxylated castor oil, a first compound, and a second compound. The first compound and the second compound can be selected from; N-lauroyl sarcosi...
Gespeichert in:
Hauptverfasser: | , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | VO, NGOC TRUCI KING-SMITH, DOMINIC HULL, WADE |
description | In one example presented herein, is a pharmaceutical composition. The pharmaceutical composition can include halobetasol propionate, from 0 wt% to 3 wt% ethoxylated castor oil, a first compound, and a second compound. The first compound and the second compound can be selected from; N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate. The first compound and the second compound are not the same.
Un exemple de la présente invention concerne une composition pharmaceutique. La composition pharmaceutique peut comprendre du propionate d'halobétasol, de 0 % en poids à 3 % en poids d'huile de ricin éthoxylée, un premier composé et un second composé. Le premier composé et le deuxième composé peuvent être choisis parmi : la N-lauroyl-sarcosine, l'octylsulfate de sodium, le laurate de méthyle, le myristate d'isopropyle, l'acide oléique, l'oléate de glycéryle et le laurylsulfoacétate de sodium. Le premier composé et le deuxième composé ne sont pas identiques. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3040867A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3040867A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3040867A13</originalsourceid><addsrcrecordid>eNrjZFD2cPTxd3INcQz291EICPIP8PT3cwxxVXD29w3wD_YMAXKDeRhY0xJzilN5oTQ3g4Kba4izh25qQX58anFBYnJqXmpJvLOjsYGJgYWZuaOhMRFKAD3KIp4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>HALOBETASOL PROPIONATE COMPOSITIONS</title><source>esp@cenet</source><creator>VO, NGOC TRUCI ; KING-SMITH, DOMINIC ; HULL, WADE</creator><creatorcontrib>VO, NGOC TRUCI ; KING-SMITH, DOMINIC ; HULL, WADE</creatorcontrib><description>In one example presented herein, is a pharmaceutical composition. The pharmaceutical composition can include halobetasol propionate, from 0 wt% to 3 wt% ethoxylated castor oil, a first compound, and a second compound. The first compound and the second compound can be selected from; N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate. The first compound and the second compound are not the same.
Un exemple de la présente invention concerne une composition pharmaceutique. La composition pharmaceutique peut comprendre du propionate d'halobétasol, de 0 % en poids à 3 % en poids d'huile de ricin éthoxylée, un premier composé et un second composé. Le premier composé et le deuxième composé peuvent être choisis parmi : la N-lauroyl-sarcosine, l'octylsulfate de sodium, le laurate de méthyle, le myristate d'isopropyle, l'acide oléique, l'oléate de glycéryle et le laurylsulfoacétate de sodium. Le premier composé et le deuxième composé ne sont pas identiques.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180426&DB=EPODOC&CC=CA&NR=3040867A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180426&DB=EPODOC&CC=CA&NR=3040867A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>VO, NGOC TRUCI</creatorcontrib><creatorcontrib>KING-SMITH, DOMINIC</creatorcontrib><creatorcontrib>HULL, WADE</creatorcontrib><title>HALOBETASOL PROPIONATE COMPOSITIONS</title><description>In one example presented herein, is a pharmaceutical composition. The pharmaceutical composition can include halobetasol propionate, from 0 wt% to 3 wt% ethoxylated castor oil, a first compound, and a second compound. The first compound and the second compound can be selected from; N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate. The first compound and the second compound are not the same.
Un exemple de la présente invention concerne une composition pharmaceutique. La composition pharmaceutique peut comprendre du propionate d'halobétasol, de 0 % en poids à 3 % en poids d'huile de ricin éthoxylée, un premier composé et un second composé. Le premier composé et le deuxième composé peuvent être choisis parmi : la N-lauroyl-sarcosine, l'octylsulfate de sodium, le laurate de méthyle, le myristate d'isopropyle, l'acide oléique, l'oléate de glycéryle et le laurylsulfoacétate de sodium. Le premier composé et le deuxième composé ne sont pas identiques.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFD2cPTxd3INcQz291EICPIP8PT3cwxxVXD29w3wD_YMAXKDeRhY0xJzilN5oTQ3g4Kba4izh25qQX58anFBYnJqXmpJvLOjsYGJgYWZuaOhMRFKAD3KIp4</recordid><startdate>20180426</startdate><enddate>20180426</enddate><creator>VO, NGOC TRUCI</creator><creator>KING-SMITH, DOMINIC</creator><creator>HULL, WADE</creator><scope>EVB</scope></search><sort><creationdate>20180426</creationdate><title>HALOBETASOL PROPIONATE COMPOSITIONS</title><author>VO, NGOC TRUCI ; KING-SMITH, DOMINIC ; HULL, WADE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3040867A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2018</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>VO, NGOC TRUCI</creatorcontrib><creatorcontrib>KING-SMITH, DOMINIC</creatorcontrib><creatorcontrib>HULL, WADE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>VO, NGOC TRUCI</au><au>KING-SMITH, DOMINIC</au><au>HULL, WADE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>HALOBETASOL PROPIONATE COMPOSITIONS</title><date>2018-04-26</date><risdate>2018</risdate><abstract>In one example presented herein, is a pharmaceutical composition. The pharmaceutical composition can include halobetasol propionate, from 0 wt% to 3 wt% ethoxylated castor oil, a first compound, and a second compound. The first compound and the second compound can be selected from; N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate. The first compound and the second compound are not the same.
Un exemple de la présente invention concerne une composition pharmaceutique. La composition pharmaceutique peut comprendre du propionate d'halobétasol, de 0 % en poids à 3 % en poids d'huile de ricin éthoxylée, un premier composé et un second composé. Le premier composé et le deuxième composé peuvent être choisis parmi : la N-lauroyl-sarcosine, l'octylsulfate de sodium, le laurate de méthyle, le myristate d'isopropyle, l'acide oléique, l'oléate de glycéryle et le laurylsulfoacétate de sodium. Le premier composé et le deuxième composé ne sont pas identiques.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; fre |
recordid | cdi_epo_espacenet_CA3040867A1 |
source | esp@cenet |
subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
title | HALOBETASOL PROPIONATE COMPOSITIONS |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T03%3A09%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=VO,%20NGOC%20TRUCI&rft.date=2018-04-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3040867A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |